4,548 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by Diametric Capital LP

Diametric Capital LP purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 4,548 shares of the biopharmaceutical company’s stock, valued at approximately $217,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Quantbot Technologies LP bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $150,000. HighTower Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 20.2% in the third quarter. HighTower Advisors LLC now owns 36,174 shares of the biopharmaceutical company’s stock valued at $2,080,000 after buying an additional 6,075 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Halozyme Therapeutics by 6.2% in the third quarter. Janus Henderson Group PLC now owns 545,173 shares of the biopharmaceutical company’s stock valued at $31,204,000 after buying an additional 31,871 shares in the last quarter. Stifel Financial Corp lifted its position in shares of Halozyme Therapeutics by 126.3% during the 3rd quarter. Stifel Financial Corp now owns 17,121 shares of the biopharmaceutical company’s stock valued at $980,000 after acquiring an additional 9,555 shares during the last quarter. Finally, EP Wealth Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth $357,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the transaction, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,200 shares of company stock valued at $1,786,668. Insiders own 2.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Wells Fargo & Company cut their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Piper Sandler raised their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Finally, Benchmark restated a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $63.02 on Thursday. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The firm has a market capitalization of $7.79 billion, a price-to-earnings ratio of 18.37, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The company has a 50 day simple moving average of $59.62 and a 200-day simple moving average of $54.90. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. The firm had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.